Abstract：
BACKGROUND: Acute myocardial infarction (AMI) is a serious condition with high mortality rates. Early risk stratification is of significant importance to assess the prognosis. Insulin-like growth factor-binding protein 5 (IGFBP5) levels in AMI patients and its potential as a prognosis biomarker were unclear.
OBJECTIVE: To investigate serum IGFBP5 levels in AMI and its prognostic value for short-term major adverse cardiovascular events (MACE).
METHODS: We collected serum IGFBP5 levels from 200 patients with new-onset AMI and 71 coronary heart disease (CAD) patients without AMI. Linear regression was used to analyze the relationship between IGFBP5 and baseline variables. AMI patients were followed up, and the risk of major adverse cardiovascular events (MACE) was assessed using Kaplan-Meier curve, multivariate Cox models and restricted cubic spline (RCS) analysis.
RESULTS: During a median follow-up of 217 days, 40 patients developed MACE. Serum IGFBP5 was associated with serum cardiac troponin T (cTnT) and C-reactive protein (CRP) (P = 0.013 and P = 0.013). In multivariable survival analyses, higher IGFBP5 was associated with an increased risk of MACE [HR = 1.183, 95%CI (1.104, 1.268), P < 0.001)]. There was a positive and linear association between IGFBP5 levels and the occurrence of MACE (P for nonlinearity = 0.283). The positive association between IGFBP5 and MACE risk consist across subgroups characterized by demographics and comorbidities.
CONCLUSIONS: Serum IGFBP5 was highly expressed in patients with AMI and positively associated with the short-term risk of MACE. Circulating IGFBP5 may be a diagnostic and prognostic indicator for AMI, and further studies with larger sample and longer follow-up are warranted.
OBJECTIVE: To investigate serum IGFBP5 levels in AMI and its prognostic value for short-term major adverse cardiovascular events (MACE).
METHODS: We collected serum IGFBP5 levels from 200 patients with new-onset AMI and 71 coronary heart disease (CAD) patients without AMI. Linear regression was used to analyze the relationship between IGFBP5 and baseline variables. AMI patients were followed up, and the risk of major adverse cardiovascular events (MACE) was assessed using Kaplan-Meier curve, multivariate Cox models and restricted cubic spline (RCS) analysis.
RESULTS: During a median follow-up of 217 days, 40 patients developed MACE. Serum IGFBP5 was associated with serum cardiac troponin T (cTnT) and C-reactive protein (CRP) (P = 0.013 and P = 0.013). In multivariable survival analyses, higher IGFBP5 was associated with an increased risk of MACE [HR = 1.183, 95%CI (1.104, 1.268), P < 0.001)]. There was a positive and linear association between IGFBP5 levels and the occurrence of MACE (P for nonlinearity = 0.283). The positive association between IGFBP5 and MACE risk consist across subgroups characterized by demographics and comorbidities.
CONCLUSIONS: Serum IGFBP5 was highly expressed in patients with AMI and positively associated with the short-term risk of MACE. Circulating IGFBP5 may be a diagnostic and prognostic indicator for AMI, and further studies with larger sample and longer follow-up are warranted.
摘要：
背景：急性心肌梗死（AMI）是一种严重的疾病，死亡率很高。早期危险分层对评估预后具有重要意义。胰岛素样生长因子结合蛋白5（IGFBP5）在AMI患者中的水平及其作为预后生物标志物的潜力尚不清楚。
目的：探讨血清IGFBP5在AMI中的水平及其对短期主要不良心血管事件（MACE）的预后价值。
方法：我们收集了200例新发AMI患者和71例无AMI的冠心病（CAD）患者的血清IGFBP5水平。采用线性回归分析IGFBP5与基线变量之间的关系。对AMI患者进行随访,使用Kaplan-Meier曲线评估主要不良心血管事件（MACE）的风险，多元Cox模型和约束三次样条(RCS)分析。
结果：在217天的中位随访中，40例患者发生MACE。血清IGFBP5与血清肌钙蛋白T(cTnT)和C反应蛋白(CRP)相关(P=0.013和P=0.013)。在多变量生存分析中，较高的IGFBP5与MACE风险增加相关[HR=1.183,95CI(1.104,1.268),P<0.001)]。IGFBP5水平与MACE的发生呈正线性相关（非线性P=0.283）。IGFBP5和MACE风险之间的正相关包括以人口统计学和合并症为特征的亚组。
结论：血清IGFBP5在AMI患者中高表达，并与MACE的短期风险呈正相关。循环IGFBP5可能是AMI的诊断和预后指标，需要更大样本和更长时间随访的进一步研究.
目的：探讨血清IGFBP5在AMI中的水平及其对短期主要不良心血管事件（MACE）的预后价值。
方法：我们收集了200例新发AMI患者和71例无AMI的冠心病（CAD）患者的血清IGFBP5水平。采用线性回归分析IGFBP5与基线变量之间的关系。对AMI患者进行随访,使用Kaplan-Meier曲线评估主要不良心血管事件（MACE）的风险，多元Cox模型和约束三次样条(RCS)分析。
结果：在217天的中位随访中，40例患者发生MACE。血清IGFBP5与血清肌钙蛋白T(cTnT)和C反应蛋白(CRP)相关(P=0.013和P=0.013)。在多变量生存分析中，较高的IGFBP5与MACE风险增加相关[HR=1.183,95CI(1.104,1.268),P<0.001)]。IGFBP5水平与MACE的发生呈正线性相关（非线性P=0.283）。IGFBP5和MACE风险之间的正相关包括以人口统计学和合并症为特征的亚组。
结论：血清IGFBP5在AMI患者中高表达，并与MACE的短期风险呈正相关。循环IGFBP5可能是AMI的诊断和预后指标，需要更大样本和更长时间随访的进一步研究.
